Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod

Retrieved on: 2020-12-02 16:54:40

Tags for this article:

Click the tags to see associated articles and topics

Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod. View article details on hiswai:

Excerpt

The FDA has approved <b>Roche</b> and Blueprint Medicines' Gavreto in advanced or metastatic RET-mutant medullary or RET fusion-positive thyroid ...

Article found on: www.fiercepharma.com